{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:36:55Z","timestamp":1783388215334,"version":"3.54.6"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Pharmasolutions Contract Research Organization"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The effect of gender and body mass index (BMI) on the pharmacokinetics of rivastigmine was studied in Egyptian human subjects using new bio-analytical validated LC\/MS\/MS method. In this study, Rivastigmine was estimated in human plasma using Escitalopram as an internal standard (IS). Rivastigmine and Escitalopram were extracted from human plasma samples by liquid\u2013liquid extraction using diethyl ether (DEE)\u2013dichloromethane (DCM) (70:30, v\/v). Chromatographic separation was performed on a reversed phase C18 INERTSIL ODS column using 0.05% aqueous formic acid, acetonitrile in the ratio (50:50, v\/v) as a mobile phase. Multiple reaction monitoring (MRM) was applied and operated by positive mode electrospray ionization. A significant difference between male and female Cmax (maximum plasma concentration) (P\u00a0=\u20090.0205; CL\u2009=\u200995.4) was found using Mann\u2013Whitney U test. Also, a moderate negative correlation was found between BMI and Tmax (time to peak plasma concentration) using spearman rho test. The calculated results confirm the difference of Rivastigmine pharmacokinetics between male and female subjects. Furthermore, it indicates that Rivastigmine dose adjustment may be necessary. The method was applied for the estimation of pharmacokinetic parameters in volunteers (n\u00a0=\u200926, 17 male and 9 female) and the effects of gender and BMI were investigated.<\/jats:p>","DOI":"10.1093\/chromsci\/bmac046","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T22:21:02Z","timestamp":1656109262000},"page":"453-460","source":"Crossref","is-referenced-by-count":3,"title":["Validated LC\/MS\/MS Method for the Determination of Rivastigmine in Human Plasma: Application to a Pharmacokinetic Study in Egyptian Volunteers to Determine the Effect of Gender and Body Mass Index"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9882-1103","authenticated-orcid":false,"given":"Ehab F","family":"ElKady","sequence":"first","affiliation":[{"name":"Pharmaceutical Chemistry Department , Faculty of Pharmacy, , Kasr El-Aini St., Cairo 11562 , Egypt"},{"name":"Cairo University , Faculty of Pharmacy, , Kasr El-Aini St., Cairo 11562 , Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0570-5731","authenticated-orcid":false,"given":"Eman A","family":"Mostafa","sequence":"additional","affiliation":[{"name":"Pharmaceutical Chemistry Department , Faculty of Pharmacy, , Kasr El-Aini St., Cairo 11562 , Egypt"},{"name":"Cairo University , Faculty of Pharmacy, , Kasr El-Aini St., Cairo 11562 , Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"2023060110423952000_ref1","volume-title":"Exelon product information"},{"key":"2023060110423952000_ref2","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0149-2918(03)80160-1","article-title":"A review of rivastigmine: a reversible cholinesterase inhibitor","volume":"25","author":"","year":"2003","journal-title":"Clin. Therapeutic."},{"key":"2023060110423952000_ref3","first-page":"89","volume-title":"Alzheimer\u2019s disease clinical and treatment perspectives","author":"Bowen","year":"1995"},{"key":"2023060110423952000_ref4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/WNL.50.3.669","article-title":"Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer\u2019s disease","volume":"50","author":"Farlow","year":"1998","journal-title":"Journal of Neurology"},{"key":"2023060110423952000_ref5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0021-5198(19)31381-2","article-title":"From Molecular Structure to Alzheimer Therapy","volume":"74","author":"Giacobini","year":"1997","journal-title":"Japanese Journal of Pharmacology"},{"key":"2023060110423952000_ref6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0028-3908(99)00157-4","article-title":"Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats","volume":"39","author":"Wang","year":"2000","journal-title":"Neuropharmacology"},{"key":"2023060110423952000_ref7","first-page":"493","article-title":"Gender differences in the pharmacokinetics of rivastigmine in rats","volume":"59","author":"Arumugam","year":"2009","journal-title":"Arzneimittel-Forschung"},{"key":"2023060110423952000_ref8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.kjms.2017.04.006","article-title":"Factors affecting therapeutic response to Rivastigmine in Alzheimer\u2019s disease patients in Taiwan","volume":"33","author":"Chen","year":"2017","journal-title":"The Kaohsiung Journal of Medical Sciences"},{"key":"2023060110423952000_ref9","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial","volume":"318","author":"Rosler","year":"1999","journal-title":"BMJ"},{"key":"2023060110423952000_ref10","first-page":"292","article-title":"Neurol. Neurosurg","volume":"75","author":"Adler","year":"2004","journal-title":"Psychiatry"},{"key":"2023060110423952000_ref11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/(SICI)1099-1166(199809)13:9<625::AID-GPS835>3.0.CO;2-2","article-title":"Effect of sex and apolipoprotein E genotype on response to anthicholinesterase therapy in Alzheimer\u2019s disease","volume":"13","author":"MacGowan","year":"1998","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"2023060110423952000_ref12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00008571-200207000-00009","article-title":"Presence or absence of at least one \u03b54 allele and gender are not predictive for the response to donepezil treatment in Alzheimer\u2019s disease","volume":"12","author":"Rigaud","year":"2002","journal-title":"Pharmacogenetics"},{"key":"2023060110423952000_ref13","first-page":"457","article-title":"et\u00a0al","volume":"14","author":"Ferretti","year":"2018","journal-title":"Nature review"},{"key":"2023060110423952000_ref14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/bmc.1455","article-title":"Development and validation of a HPLC method for quantification of rivastigmine in rat urine and identification of a novel metabolite in urine by LC-MS\/MS","volume":"25","author":"Arumugam","year":"2011","journal-title":"Biomedical Chromatography"},{"key":"2023060110423952000_ref15","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/rcm.2737","article-title":"A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry","volume":"20","author":"Frankfort","year":"2006","journal-title":"Rapid Communications in Mass Spectrometry"},{"key":"2023060110423952000_ref16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1570-0232(02)00816-4","article-title":"Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry","volume":"784","author":"Pommier","year":"2003","journal-title":"Journal of Chromatography B"},{"key":"2023060110423952000_ref17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/bmc.304","article-title":"A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry","volume":"18","author":"Enz","year":"2004","journal-title":"Biomedical Chromatography"},{"key":"2023060110423952000_ref18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchromb.2007.01.003","article-title":"A rapid and sensitive liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS\/MS) method for the estimation of rivastigmine in human plasma","volume":"852","author":"Jignesh","year":"2007","journal-title":"Journal of Chromatography B"},{"key":"2023060110423952000_ref19","first-page":"115","article-title":"High-Performance Liquid Chromatographic Determination of Rivastig-mine in Human Plasma for Application in Pharmacokinetic Studies","volume":"9","author":"Amini","year":"2010","journal-title":"IJPR"},{"key":"2023060110423952000_ref20","first-page":"1","article-title":"Guideline on bioanalytical method validation","volume":"44","author":"EMA","year":"2012","journal-title":"Comm. Med. Prod. Hum. Use"},{"key":"2023060110423952000_ref21","article-title":"Guidance for industry: bioanalytical method validation","author":"Food and Drug Administration","year":"2018","journal-title":"U.S.Dep.Heal.Hum.Serv."},{"key":"2023060110423952000_ref22","article-title":"Declaration of Helsinki Historical & Contemporary Perspective","author":"Human","year":"2001","journal-title":"World Medical Association."},{"key":"2023060110423952000_ref23","first-page":"69","article-title":"Statistics corner: A guide to appropriate use of correlation coefficient in medical research","volume":"24","author":"Mukaka","year":"2012","journal-title":"Malawi Medical Journal"},{"key":"2023060110423952000_ref24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4103\/0019-5154.182416","article-title":"Biostatistics series module 6: Correlation and linear regression","volume":"61","author":"Hazra","year":"2016","journal-title":"Indian Journal of Dermatology"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/61\/5\/453\/50487135\/bmac046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/61\/5\/453\/50487135\/bmac046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T10:43:03Z","timestamp":1685616183000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/61\/5\/453\/6617664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,6,25]]},"published-print":{"date-parts":[[2023,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmac046","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2022,6,25]]}}}